Summary
The new competitive histamine H2-receptor antagonist, ramixotidine 2 HCl (CM 57755), has been tested in healthy male volunteers for its ability to inhibit pentagastrin-stimulated gastric acid secretion. In the first study, in 8 subjects, pentagastrin 6 µg·kg−1 was injected s.c., 90 min after the following 4 oral treatments given in random order at weekly intervals: placebo, 100, 200 and 400 mg CM 57755. Gastric contents were collected over 15-min periods during the 2 h after pentagastrin stimulation. In a second, similar study, 8 subjects received placebo, 0.5 and 1.0 g CM 57755 and 800 mg cimetidine, 120 min before a 2 h i.v. infusion of 6 µg·kg−1·h−1 pentagastrin. Cumulative gastric secretion in placebo-treated subjects was 46±14 and 62±11 mmol H+·2 h−1 (mean±SD), respectively, in the first and second studies. It was significantly reduced only after 400 mg CM 57755 in the first study. In the second study either dose of CM 57755 and cimetidine caused a significant reduction in gastric acid secretion. Average plasma levels of ramixotidine were dose-related after 0.2 and 1.0 g and ranged from 0.3 and 1.6 µg/ml, respectively, at 60 min to 0.5 and 3.7 µg/ml at 180 min. The peak cimetidine level averaged 3.6 µg/ml at 150 min. Individual CM 57755 plasma levels throughout the test period were fairly consistent with the inhibition of cumulative gastric acid secretion scored concurrently in each subject. No subjective side-effects attributable to the treatments were reported, and no abnormal findings were seen in the ECG or in laboratory tests.
Similar content being viewed by others
References
Lavezzo A, Manzoni L, Bianchetti A, Manara L (1986) Inhibition of dimaprit- and pentagastrin-induced gastric acid secretion in cats by the new histamine H2-antagonist, CM 57755. J Pharm Pharmacol 38: 853–856
Bianchetti A, Lavezzo A, Manara L, Manzoni L, Picerno N (1985) Effects of cimetidine, ranitidine and the new H2-receptor antagonist CM 57755 on drug metabolism in rats. Br J Pharmacol 86: 790P
Wilson JA, Johnston D, Penston J, Wormsley KG (1986) Gastric inhibitory effects of CM 57755. A new histamine H2 receptor antagonist. Eur J Clin Pharmacol 30: 33–36
Konturek SJ, Obtulowicz W, Kwiecien N, Sito E, Mikos E, Oleksy J (1980) Comparison of ranitidine and cimetidine in the inhibition of histamine, sham-feeding, and meal-induced gastric secretion in duodenal ulcer patients. Gut 21: 181–186
Soldani G, Mengozzi G, Polloni A (1986) Effects of CM 57755 on gastric acid secretion and gastrin release in the dog. Dig Dis Sci 31: 394S
Necciari J, Mery D, Garriot P, Escourrou J, Cautreels W (1985) Pharmacokinetics of CM 57755, a new-histamine H2-receptor antagonist, after single oral doses in man. Int J Clin Pharm Res 6: 457–465
Domschke W, Lux G, Domschke S (1980) Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine. Gastroenterology 79: 1267–1271
Lebert PA, MacLeod SM, Mahon WA, Soldin SJ, Vandenberghe HM (1981) Ranitidine kinetics and dynamics. Clin Pharmacol Ther 30: 539–544
Pancorbo S, Bubrick MP, Chin TWF, Miller KW, Onstad G (1984) Cimetidine dynamics after repeated intravenous injection. Clin Pharmacol Ther 35: 50–54
Holloway RH, Kuljian B, Eshelman F, McCallum RW (1984) Effects of ranitidine and of cimetidine on pentagastrin-stimulated gastric acid secretion. Clin Pharmacol Ther 35: 203–207
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brassinne, A., Dresse, A., Basilisco, G. et al. Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers. Eur J Clin Pharmacol 32, 467–470 (1987). https://doi.org/10.1007/BF00637671
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637671